Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.38 |
| ▸ | TUBB | P07437 | 4/20 | 0.38 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.38 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.38 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.38 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.38 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.38 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.38 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.38 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.38 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.38 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6531077 | 0.87 | TUBB4A (0.43) | CDK2MAPTSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL5026571 | 0.87 | TUBB4A (0.43) | CDK2MAPTSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL5025192 | 0.84 | PPARG (0.42) | KDM4ELMNANPSR1KDRPPARG | |
| SCHEMBL4026844 | 0.79 | MAPT (0.46) | MAPTSMN1; SMN2ALDH1A1HTTF2RL3 | |
| SCHEMBL4026840 | 0.79 | MAPT (0.46) | MAPTSMN1; SMN2ALDH1A1HTTF2RL3 | |
| SCHEMBL5018020 | 0.78 | ABCB11 (0.41) | MAPTSMN1; SMN2ALDH1A1RXFP1KMT2A | |
| SCHEMBL5022868 | 0.78 | MAPT (0.39) | CDK2MAPTSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL5018009 | 0.77 | AR (0.46) | MEN1KMT2AKDRPPARG | |
| SCHEMBL5022815 | 0.76 | AR (0.50) | TUBB4ATUBBTUBA3CTUBA1BTUBA4A | |
| SCHEMBL5016465 | 0.76 | KDM4E (0.40) | CDK2MAPTSMN1; SMN2ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146810-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-06-19 | — | — | US | disclosed |
| EP-1554262-B1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LTD (IN) | 2007-12-05 | — | — | EP | disclosed |
| US-7238725-B2 | Tricyclic compounds useful for the treatment of inflammatory and allergic disorders: process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS LTD. (IN) | 2007-07-03 | — | — | US | disclosed |
| US-20060178418-A1 | Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation and pharmaceutical compositions containing them | GLENMARK PHARMACEUTICALS LTD. (IN) | 2006-08-10 | — | — | US | disclosed |
| EP-1554262-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Glenmark Pharmaceuticals Limited (IN) | 2005-07-20 | — | — | EP | disclosed |
| WO-2004037805-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | GLENMARK PHARMACEUTICALS LTD. (US) | 2004-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146810-A1 | NOVEL TRICYCLIC COMPOUNDS USEFUL FOR THE TREATMENT OF INFLAMMATORY AND ALLERGIC DISORDERS: PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LTC4S, TSLP, GPR119 | CDK2 1356/4885MAPT 783/4885SMN1; SMN2 3144/4885 |
| US-20060178418-A1 | Novel tricyclic compounds useful for the treatment of inflammatory and allergic disorders:process for their preparation and pharmaceutical compositions containing them | LTC4S, TSLP, GPR119 | CDK2 1356/4885MAPT 783/4885SMN1; SMN2 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.